AbbVie’s JUVMO wins FDA approval for Parkinson’s disease

AbbVie has received US Food and Drug Administration (FDA) approval for JUVMO (tavapadon), a once-daily oral treatment for Parkinson’s disease in adults and the first approved selective D1/D5 receptor agonist for the condition.

The FDA approval, listed among the agency’s 2026 novel drug approvals, covers JUVMO for the treatment of Parkinson’s disease in adults. AbbVie expects the medicine to become available to US patients in October 2026.

The approval gives AbbVie another commercial asset in neuroscience and strengthens its Parkinson’s disease portfolio. Tavapadon was acquired by AbbVie through its $8.7bn acquisition of Cerevel Therapeutics in 2023, which brought the drug into AbbVie’s development pipeline.

JUVMO introduces a different dopamine-targeting approach

JUVMO selectively targets D1/D5 dopamine receptors, distinguishing it from established dopamine agonists that primarily target D2/D3 receptors.

AbbVie said the treatment is designed to provide motor-symptom control either on its own or alongside oral levodopa. The company positions the medicine as a new option across different stages of Parkinson’s disease management.

Parkinson’s disease is a progressive neurological disorder associated with symptoms including tremor, muscle rigidity, slowed movement and balance difficulties. AbbVie estimates that more than 11 million people worldwide are living with the condition.

As the disease progresses, patients can experience fluctuations between periods when symptoms are controlled and periods when movement symptoms return. Dyskinesia, or involuntary movement, can also occur as treatment continues.

FDA approval supported by Phase 3 TEMPO programme

The FDA decision was supported by data from AbbVie’s Phase 3 TEMPO clinical development programme.

TEMPO-1 and TEMPO-2 evaluated tavapadon in people with early Parkinson’s disease who were not taking oral levodopa, while TEMPO-3 studied JUVMO as an adjunct to oral levodopa in patients experiencing motor fluctuations.

In TEMPO-1, JUVMO produced statistically significant improvements in activities of daily living compared with placebo at week 26, based on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II.

The combined Part II and Part III measure, covering activities of daily living and motor symptoms, also improved significantly compared with placebo.

TEMPO-2 produced statistically significant improvements in both the Part II measure and the combined Part II and III score at week 26.

In TEMPO-3, patients receiving JUVMO alongside oral levodopa experienced an increase in daily “on” time without troublesome dyskinesia of 1.7 hours, compared with 0.6 hours for placebo plus levodopa at week 26. Daily “off” time fell by 1.9 hours in the JUVMO group, compared with 0.9 hours in the placebo group.

AbbVie expects US JUVMO launch in October

AbbVie said it expects JUVMO to become available to US patients in October 2026. The medicine is supplied in 5mg, 10mg and 15mg tablets, with 0.25mg and 1mg tablets available in a titration pack.

The launch will add a new product to AbbVie’s neuroscience portfolio at a time when the company is seeking to expand its sources of growth beyond established medicines.

AbbVie reported $16.99bn in worldwide revenue for the second quarter of 2026, up 10.2% on a reported basis, while its neuroscience business remains one of the company’s key therapeutic areas.

Reuters reported that analysts expect the Parkinson’s launch to build gradually as reimbursement discussions progress. The company has continued to target more than $5bn in combined Parkinson’s disease sales across its franchise, according to Citi analysts cited by Reuters.

Safety profile and treatment considerations

The TEMPO programme reported that most treatment-emergent adverse events were non-serious and mild or moderate in severity.

For patients receiving JUVMO without oral levodopa, the most commonly reported adverse events included nausea, headache, dizziness, fatigue, changes in taste, vomiting, dry mouth and anxiety.

When JUVMO was administered with oral levodopa, commonly reported adverse events included nausea, dyskinesia, dizziness, headache, hallucinations and orthostatic hypotension.

AbbVie’s prescribing information also warns about low blood pressure, unusual urges, hallucinations and uncontrolled movements. These safety considerations will form part of clinical decision-making as physicians begin using the medicine.

What JUVMO means for AbbVie’s Parkinson’s portfolio

The FDA approval gives AbbVie a new oral treatment with a mechanism that differs from existing dopamine agonists.

The commercial opportunity will depend on how neurologists position JUVMO within treatment pathways, including its use in early Parkinson’s disease and alongside levodopa for patients experiencing motor fluctuations.

The product also adds another potential source of growth to AbbVie’s neuroscience portfolio. Reuters reported that AbbVie already has Parkinson’s treatments including Vyalev and Duopa, with the company targeting more than $5bn in combined Parkinson’s sales.

For the wider pharmaceutical market, the approval introduces a new mechanism into Parkinson’s treatment and provides another option for managing motor symptoms.

Market Signal: JUVMO’s approval strengthens AbbVie’s position in Parkinson’s disease while introducing the first approved selective D1/D5 receptor agonist into the US market. The next commercial indicators will be US availability, physician adoption, reimbursement coverage and the trajectory of sales following the October launch.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates.